Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

University of Toronto

$135,000.00

Development of specific ubiquitin-based inhibitors targeting oncogenic deubiquitinating enzyme USP1

FY 2011-12

Summary
Effective strategies to treat cancer rely on our ability to interfere with cellular processes that are deregulated in tumors. One such biological process is the regulation of protein stability by a small protein called ubiquitin, which attaches to other proteins and acts as a signal for their destruction. This process is regulated by various enzymes, which add or remove the ubiquitin label. In recent years, deubiquitinating enzymes (DUBs), which catalyze the removal of ubiquitin, have attracted increasing attention as novel targets for drug development because they are crucial mediators of key intracellular processes. In humans, there are nearly 100 DUBs, including a subgroup called ubiquitin-specific proteases (USPs). One of these USPs, USP1, has recently emerged as a promising target for pharmacological intervention in the most common bone cancer, osteosarcoma. Preventing USP1's activity in osteosarcoma is predicted to reduce cell growth and decrease spreading of cancer cells to other organs, and to render cells more sensitive to chemotherapeutic agents. Unfortunately, the lack of selective molecules to prevent USP1 functions, called inhibitors, has severely hampered attempts to manipulate it for therapeutic benefits. The goal of my post-doctoral training is to develop highly specific and potent inhibitors for USP1. Using state-of-the-art protein engineering technology, I propose to make ubiquitin-like molecules that will associate tightly with USP1 in a manner that will block its catalytic function, and thus, act as inhibitors. I will also create a system to inhibit USP1 in human cells in a controllable way. Finally, I will characterize these inhibitors in osteosarcoma cells to confirm their ability to interfere with USP1's biological functions. In conclusion, this work will generate invaluable tools to understand and modulate USP1 activity in human cells and will shed light on effective cancer therapy of aggressive malignant osteosarcoma.
Program
CIHR Fellowship
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
254956
Name
Zhang Wei
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Development of specific ubiquitin-based inhibitors targeting oncogenic deubiquitinating enzyme USP1
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cancer Therapy; Combinatorial Libraries; Deubiquitination; High Throughput Screening; Osteosarcoma; Phage Display; Protein Engineering; Ubiquitin; Usp1
Abstract
Effective strategies to treat cancer rely on our ability to interfere with cellular processes that are deregulated in tumors. One such biological process is the regulation of protein stability by a small protein called ubiquitin, which attaches to other proteins and acts as a signal for their destruction. This process is regulated by various enzymes, which add or remove the ubiquitin label. In recent years, deubiquitinating enzymes (DUBs), which catalyze the removal of ubiquitin, have attracted increasing attention as novel targets for drug development because they are crucial mediators of key intracellular processes. In humans, there are nearly 100 DUBs, including a subgroup called ubiquitin-specific proteases (USPs). One of these USPs, USP1, has recently emerged as a promising target for pharmacological intervention in the most common bone cancer, osteosarcoma. Preventing USP1's activity in osteosarcoma is predicted to reduce cell growth and decrease spreading of cancer cells to other organs, and to render cells more sensitive to chemotherapeutic agents. Unfortunately, the lack of selective molecules to prevent USP1 functions, called inhibitors, has severely hampered attempts to manipulate it for therapeutic benefits. The goal of my post-doctoral training is to develop highly specific and potent inhibitors for USP1. Using state-of-the-art protein engineering technology, I propose to make ubiquitin-like molecules that will associate tightly with USP1 in a manner that will block its catalytic function, and thus, act as inhibitors. I will also create a system to inhibit USP1 in human cells in a controllable way. Finally, I will characterize these inhibitors in osteosarcoma cells to confirm their ability to interfere with USP1's biological functions. In conclusion, this work will generate invaluable tools to understand and modulate USP1 activity in human cells and will shed light on effective cancer therapy of aggressive malignant osteosarcoma.
Competitiondate
201202
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Zhang, Wei
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~
University of Toronto - $135,000 Grant (2011-12) | Canada Spends